Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
NCT05019976 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2025-12-29
Summary
This study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma. Treatment radiation over 5-6 weeks is often standard of care for many people with lymphoma, but doctors leading this study aim to find out if using radiation for a shorter period of time can be safe for treating lymphoma and if so, what is the safest shortened dose of radiation for participants.
Conditions
- Non-hodgkin Lymphoma
- Hodgkin Lymphoma
- Lymphoma
Interventions
- RADIATION
-
Radiation - Dose Level 0
Dose Per Fraction (Each Radiation Treatment): 3.2Gy to 2.4Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 44.8Gy to 33.6Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 14
- RADIATION
-
Radiation - Dose Level 1
Dose Per Fraction (Each Radiation Treatment): 4.2Gy to 3.2Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 42Gy to 32Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 10
- RADIATION
-
Radiation - Dose Level 2
Dose Per Fraction (Each Radiation Treatment): 5.2Gy to 4.2Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 39.2Gy to 29.4Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 7
- RADIATION
-
Radiation - Dose Level 3
Dose Per Fraction (Each Radiation Treatment): 6.8Gy to 5.4Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 34Gy to 27Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 5
- RADIATION
-
Radiation - Dose Level 4
Dose Per Fraction (Each Radiation Treatment): 10Gy to 7.8Gy (minimal dose) depending on what study doctor prescribes Total Dose of Radiation for Treatment Period: 30Gy to 23.4Gy (minimal dose) depending on what study doctor prescribes Total Number of Radiation Treatments: 3
Sponsors & Collaborators
-
University of Chicago
lead OTHER
Principal Investigators
-
Yasmin Hasan, MD · University of Chicago - Comprehensive Cancer Center
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-09-30
- Primary Completion
- 2027-12-01
- Completion
- 2027-12-01
Countries
- United States
Study Locations
Related Clinical Trials
-
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01955499 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Lymphoplasmacytic Lymphoma
- +7 more
-
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01896999 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
-
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
NCT03179917 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2
- Hodgkin Lymphoma
-
Radiation Therapy in Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation
NCT00031668 · Status: COMPLETED · Phase: NA
- Lymphoma
-
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
NCT00574496 · Status: COMPLETED · Phase: PHASE2
- Lymphoma
More Related Trials
-
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma
NCT04419441 ·Status: UNKNOWN
-
Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00012207 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
NCT05272384 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma
NCT05994157 ·Status: RECRUITING ·Phase: PHASE1
-
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00073918 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03210662 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma
NCT02082977 ·Status: TERMINATED ·Phase: PHASE1
-
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT03077828 ·Status: UNKNOWN ·Phase: PHASE2
-
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT04054167 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03369964 ·Status: WITHDRAWN ·Phase: PHASE1
-
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL
NCT03016871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
NCT00588094 ·Status: COMPLETED ·Phase: PHASE2
-
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed
NCT05162976 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT02227199 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00452127 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
NCT01290549 ·Status: COMPLETED ·Phase: PHASE1
-
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
NCT00515138 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT04052997 ·Status: COMPLETED ·Phase: PHASE2
-
Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
NCT00070187 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00098566 ·Status: COMPLETED
-
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT00450827 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
NCT00005803 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT01508312 ·Status: COMPLETED ·Phase: PHASE2
-
Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma
NCT06386315 ·Status: RECRUITING ·Phase: PHASE2